Disclaimer: This is a user generated content submitted by a member of the WriteUpCafe Community. The views and writings here reflect that of the author and not of WriteUpCafe. If you have any complaints regarding this post kindly report it to us.

Candidiasis is the most common yeast infection caused by Candida spp. that exist both as a commensal and pathogen. Candida albicans is generally considered as the most pathogenic member of the genus and most common cause of different types of candidiasis. It is normally present in the vagina, mouth, stomach, skin, and intestines. The immune system controls it in the body, however, during conditions such as illness, the immune system weakens, resulting in the development of infection.

Symptoms associated with the Candida infection in mouth are characterized by throat pain and nausea, whereas, symptoms of Candida infection in vagina include itching, burning, and redness in the genital area. Tools used for the diagnosis of the disease include questionnaire, comprehensive digestive stool analysis (CDSA), and laboratorial techniques such as biochemical assays.

Companies that are involved in developing therapeutics for candidiasis have shown positive clinical results in various phases of drug development. For instance, VT-1161, an orally-available inhibitor of fungal CYP51, is being developed by Mycovia Pharmaceuticals Inc. (Mycovia) for the treatment of recurrent vulvovaginal candidiasis. The phase IIb clinical trial results demonstrated that VT-1161 was well tolerable and showed an inhibitory activity against a range of Candida species.

Login

Welcome to WriteUpCafe Community

Join our community to engage with fellow bloggers and increase the visibility of your blog.
Join WriteUpCafe